Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis (REQOVERY)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sepsis
- Sponsor
- Hjalmar Bouma
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- DNA methylation (epigenetics) using the Illumina MethylationEPIC kit. Changes in DNA methylation at gene promoter/enhancer sites will be correlated through the NetworkAnalyst platform.
- Status
- Enrolling By Invitation
- Last Updated
- 2 years ago
Overview
Brief Summary
Sepsis is a life-threatening dysregulated immune response to infection associated with multi-organ failure and a high mortality rate.While researchers have focused mainly on acute sepsis, post-sepsis care of survivors has long been neglected despite the observation that many sepsis survivors suffer from debilitating post-sepsis syndrome. This syndrome is characterized by frequent hospital readmissions and increased mortality due to persistent immune dysfunction, cardiovascular disease, and cognitive impairment, causing poor quality of life and a substantial burden on the healthcare system. Disconcertingly, the number of sepsis survivors at risk for hospital readmission continues to rise.7 Of the post-sepsis symptoms, post-sepsis immunosuppression is perhaps the most clinically important. While sepsis presents as an initial phase of hyperinflammation (a "cytokine storm"), it is followed by an immunosuppressive phase that is now understood to last weeks to months and predisposes survivors to lethal secondary infections and sepsis recurrence. A third of deaths eight years post-sepsis are caused by recurrent sepsis.We hypothesize that changes in the transcriptome and DNA methylome in immune cells of survivors might be the underlying driver for prolonged immunosuppression, and may also be correlated with long-term morbidity and mortality post-sepsis, as well as other symptoms of post-sepsis syndrome including PTSD and cardiovascular disease.
Investigators
Hjalmar Bouma
Internist and Research Fellow
University Medical Center Groningen
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
DNA methylation (epigenetics) using the Illumina MethylationEPIC kit. Changes in DNA methylation at gene promoter/enhancer sites will be correlated through the NetworkAnalyst platform.
Time Frame: baseline versus 3 months follow up
The primary objective of the current project is to measure changes in DNA methylation (i.e. epigenetics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge.
Gene expression (transcriptomics/qPCR) will be measured using the Illumina Hi-Seq instrument. Differential gene expression will be correlated through the NetworkAnalyst platform.
Time Frame: baseline versus 3 months follow up
The primary objective of the current project is to measure changes in gene expression (i.e. transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge.
Secondary Outcomes
- Mortality. Mortality status will be obtained from the Municipal Personal Records Database (BRP), containing reliable and complete registration all Dutch citizens(1 year)
- Intoxications(3 months)
- Medication use(3 months)
- Physical activity (e.g. Short Questionnaire to Assess Health-Enhancing Activity) (SQUASH) and 'Utrechtse activiteiten lijst' (UAL))(3 months)
- Nutrition status measured with PS-SGA Short Form and SNAQ form. (both questionnaires)(3 months)
- Sepsis severity defined with SOFA score(3 months follow up)
- Somatic symptoms (e.g. Patient Health questionnaire-15)(3 months)
- Activities of daily living as determined by EQ-5D-5L (if abnormal also Katz-ADL-6)(3 months)
- Co-morbidity (a.o. Charlson comorbidity index)(3 months)
- Length-of-stay in hospital/intensive care unit (ICU)(0-3 months)
- Fatigue assessed with piper fatigue scale(3 months)
- Mood assessed with the Patient Health Questionnaire-2 ( (questionnaire)(3 months)
- Demographics(3 months)
- Vital parameters(At baseline and three months.)